This week's roundup of Houston innovators includes Sarah Essama of Teach for America Houston, Scott Schneider of HTX Labs, and Drs. Maria Elena Bottazzi and Peter Hotez. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to four local innovators across industries — from health tech to software — recently making headlines in Houston innovation.

Sarah Essama, director of social innovation at Teach For America Houston

Sarah Essama of Teach For America Houston shares how she innovated a new way for students themselves to learn how to innovate. Photo courtesy of Sarah Essama

As director of social innovation at Teach For America Houston, it's Sarah Essama's job to come up with new ways for the organization to support both students and teachers. But, as she explains on the Houston Innovators Podcast this week, Essama realized a huge lesson modern students needed was to learn this innovation process themselves.

This line of thinking turned into Essama founding The Dream Lab, powered by Teach for America Houston.

"The Dream Lab is a set of immersive design spaces where young people leverage their imagination and creativity to innovate and solve problems within their community," she explains.

Last month, the new concept rolled out to high school students in partnership with DivInc Houston, a nonprofit focused on social and economic equity in entrepreneurship, and 21 ninth graders spent the day at the Ion for a mini-innovation accelerator and design showcase. Click here to read more.

Scott Schneider, CEO and founder of HTX Labs

Scott Schneider of HTX Labs has something to celebrate. Photo via htxlabs.com

A Houston-based virtual reality training provider has closed its first round of funding. HTX Labs announced last month that it has received a $3.2 million investment from Cypress Growth Capital.

“We have been looking to secure outside capital to accelerate the growth of our EMPACT platform and customer base but we hadn’t found the right partner who provided an investment vehicle that matched our needs,“ says HTX Labs CEO Scott Schneider in the release. “We found everything we were looking for in Cypress Growth Capital. They have a non-dilutive funding model that aligns with our capital expectations and have the level of experience that really makes this smart money.

The fresh funding will go toward growing and scaling the company's operations — both within the current Department of Defense and expansion opportunities into key commercial markets, like heavy industry, manufacturing, and higher education. Additionally, the funding will support increased customer adoption. Click here to read more.

​Drs. Maria Elena Bottazzi and Peter Hotez 

Two Houston health care innovators got the green light to distribute their low-cost COVID-19 vaccine in Indonesia. Photo courtesy of TMC

After months of development and testing, the Houston-born COVID-19 vaccine has gotten the go-ahead to be produced and distributed in Indonesia.

IndoVac was created by the Texas Children’s Hospital Center for Vaccine Development and Baylor College of Medicine. Drs. Peter Hotez and Maria Elena Bottazzi lead the vaccine project. Bio Farma is licensing IndoVac from BCM Ventures, the commercial group at the Baylor College of Medicine.

“Access to vaccines in the developing world is critical to the eradication of this virus,” Hotez, co-director of the Texas Children’s Hospital Center for Vaccine Development and dean of the National School of Tropical Medicine at Baylor College of Medicine, says in a news release. Click here to read more.

Drs. Maria Elena Bottazzi and Peter Hotez got the green light to distribute their low-cost COVID-19 vaccine in Indonesia. Photo courtesy

Houston doctors get approval for low-cost COVID vaccine abroad

green light

A Houston-born COVID-19 vaccine has gotten the go-ahead to be produced and distributed in Indonesia.

PT Bio Farma, which oversees government-owned pharmaceutical manufacturers in Indonesia, says it’s prepared to make 20 million doses of the IndoVac COVID-19 vaccine this year and 100 million doses a year by 2024. This comes after the vaccine received authorization from the Indonesian Food and Drug Authority for emergency use in adults.

With more than 275 million residents, Indonesia is the world’s fourth most populous country.

IndoVac was created by the Texas Children’s Hospital Center for Vaccine Development and Baylor College of Medicine. Drs. Peter Hotez and Maria Elena Bottazzi lead the vaccine project. Bio Farma is licensing IndoVac from BCM Ventures, the commercial group at the Baylor College of Medicine.

“Access to vaccines in the developing world is critical to the eradication of this virus,” Hotez, co-director of the Texas Children’s Hospital Center for Vaccine Development and dean of the National School of Tropical Medicine at Baylor College of Medicine, says in a news release.

Aside from distributing the vaccine in Indonesia, Bio Farma plans to introduce it to various international markets.

“The need for a safe, effective, low-cost vaccine for middle- to low-income countries is central to the world’s fight against the COVID-19 pandemic,” says Bottazzi, co-director of the Texas Children’s Hospital Center for Vaccine Development and associate dean of the National School of Tropical Medicine at Baylor.

“Without widespread inoculation of populations in the developing world, which must include safe, effective booster doses, additional [COVID-19] variants will develop, hindering the progress achieved by currently available vaccines in the United States and other Western countries.”

Bio Farma says it has completed Phase 1 and Phase 2 clinical trials for IndoVac and is wrapping up a Phase 3 trial.

IndoVac is a version of the patent-free, low-cost Corbevax vaccine, developed in Houston and dubbed “The World’s COVID-19 Vaccine.” The vaccine formula can be licensed by a vaccine producer in any low- or middle-income country, which then can take ownership of it, produce it, name it, and work with government officials to distribute it, Hotez told The Texas Tribune in February.

Among donors that have pitched in money for development of the vaccine are the Houston-based MD Anderson and John S. Dunn foundations, the San Antonio-based Kleberg Foundation, and Austin-based Tito’s Vodka.

“During 2022, we hope to partner with the World Health Organization and other United Nations agencies to vaccinate the world. We believe that global vaccine equity is finally at hand and that it is the only thing that can bring the COVID pandemic to an end,” Hotez and Bottazzi wrote in a December 2021 article for Scientific American.

Dr. Peter Hotez and Dr. Maria Elena Bottazzi have been recognized by Fast Company for their leadership in developing low-cost COVID vaccine. Photo courtesy of Texas Children's

Houston doctors recognized among top creative leaders in business

winners

This week, Fast Company announced its 14th annual list of Most Creative People in Business — and two notable Houstonians made the cut.

Dr. Peter Hotez and his fellow dean of the National School of Tropical Medicine at Baylor College of Medicine, Dr. Maria Elena Bottazzi, were named among the list for “open sourcing a COVID-19 Vaccine for the rest of the world.” The list, which recognizes individuals making a cultural impact via bold achievements in their field, is made up of influential leaders in business.

Hotez and Bottazzi are also co-directors for the Texas Children's Hospital's Center for Vaccine Development -one of the most cutting-edge vaccine development centers in the world. For the past two decades it has acquired an international reputation as a non-profit Product Development Partnership (PDP), advancing vaccines for poverty-related neglected tropical diseases (NTDs) and emerging infectious diseases of pandemic importance. One of their most notable achievements is the development of a vaccine technology leading to CORBEVAX, a traditional, recombinant protein-based COVID-19 vaccine.

"It's an honor to be recognized not only for our team's scientific efforts to develop and test low cost-effective vaccines for global health, but also for innovation in sustainable financing that goes beyond the traditional pharma business model," says Hotez in a statement.

The technology was created and engineered by Texas Children's Center for Vaccine Development specifically to combat the worldwide problem of vaccine access and availability. Biological E Limited (BE) developed, produced and tested CORBEVAX in India where over 60 million children have been vaccinated so far.

Earlier this year, the doctors were nominated for the 2022 Nobel Peace Prize for their research and vaccine development of the vaccine. Its low cost, ease of production and distribution, safety, and acceptance make it well suited for addressing global vaccine inequity.

"We appreciate the recognition of our efforts to begin the long road to 'decolonize' the vaccine development ecosystem and make it more equitable. We hope that CORBEVAX becomes one of a pipeline of new vaccines developed against many neglected and emerging infections that adversely affect global public health," says Bottazzi in the news release from Texas Children's.

Fast Company editors and writers research candidates for the list throughout the year, scouting every business sector, including technology, medicine, engineering, marketing, entertainment, design, and social good. You can see the complete list here

.

Dr. Maria Elena Bottazzi and Dr. Peter Hotez have been nominated for their low-cost COVID vaccine. Photo courtesy of Baylor College of Medicine

2 Houston doctors nominated for Nobel Peace Prize for low-cost COVID vaccine

major moment

He’s gained national and global acclaim for his battle against COVID-19 and for his efforts, Houston’s Dr. Peter Hotez has been nominated for the 2022 Nobel Peace Prize.

Hotez, and his fellow dean of the National School of Tropical Medicine at Baylor College of Medicine, Dr. Maria Elena Bottazzi, were nominated for the iconic award by Houston Congresswoman Lizzie Fletcher (Texas-07).

The duo, who are also co-directors of the Center for Vaccine Development at Texas Children’s Hospital, were cited in a letter to the Norwegian Nobel Committee for their work to develop and distribute the low-cost Corbevax vaccine to people of the world — without patent limitation.

“My hope is that the nomination not only recognizes the importance of reducing global vaccine inequities and inequalities, but also raises the awareness regarding the importance of vaccines as lifesaving interventions and combating vaccine hesitancy in the US and globally,” Hotez tells CultureMap.

As ABC13 reports, the Nobel nominations were due Monday, January 31. In March, a shortlist is prepared and then reviewed between April and August. The winners are announced in early October and they receive their awards in Oslo, Norway on December 10.

“Dr. Hotez and Dr. Bottazzi’s effort to develop the Corbevax vaccine is truly one of international cooperation and partnership to bring health, security, and peace around the world by creating a COVID-19 vaccine and making it available and accessible to all,” Fletcher said in a statement. “It is a contribution that is of the greatest benefit to humankind.”

Hotez, one of CultureMap’s most-talked-about Houstonians in 2021, added in a statement: “I am honored that Congresswoman Fletcher would nominate us for the Nobel Peace Prize. Dr. Bottazzi and I have worked together for years, and our purpose has never changed — to bring attention to the neglected diseases of poverty and build a new generation of vaccine in the pursuit of global vaccine diplomacy. With our COVID vaccine, which is inexpensive and easy to produce, our intent was to make it available to millions of people in the world who would otherwise not have access to COVID vaccines.”

“When the COVID pandemic hit, we wanted to make a difference and had great confidence our coronavirus vaccine technology, previously developed, could lead to a global solution,” Bottazzi added. “Hopefully, it will be game changing for many countries.”

------

This article originally ran on CultureMap.

Drs. Maria Elena Bottazzi and Peter Hotez at the Center for Vaccine Development. Photo courtesy of Texas Children's Hospital

2 Houston powerhouses deploy game-changing COVID-19 worldwide vaccine

a good shot

With the U.S. logging its highest single-day total of new COVID-19 cases (441,278 infections) and some 281, 808, 270 cases documented worldwide, new treatments worldwide are in major demand — especially in emerging nations.

To that end, Texas Children’s Hospital and Baylor College of Medicine announced a new COVID vaccine ready to deploy in India and soon, other underserved countries.

Corbevax, which is dubbed “The World’s COVID-19 Vaccine,” utilizes a traditional recombinant protein-based technology that will enable production at large scales, per a press release. That means the inoculation will be widely accessible to inoculate the global population.

This new vaccine was developed at Texas Children’s Hospital CVD and led by co-directors Drs. Maria Elena Bottazzi and Peter Hotez — and in-licensed from BCM Ventures, Baylor College of Medicine’s integrated commercialization team, to Hyderabad-based vaccine and pharmaceutical company Biological E. Limited (BE).

After completing two Phase III clinical trials involving more than 3000 subjects the vaccine was found to be safe, well tolerated, and immunogenic. Current research shows Corbevax notably effective against the Ancestral-Wuhan strain and the globally dominant Delta variant, press materials note.

Safe, streamlined, low-cost vaccines for middle- to low-income countries are central to the world’s fight against the COVID-19 pandemic, the two Houston organizations note. Indeed, without widespread vaccination of populations in the Global South, additional virus variants will arise, hindering the progress achieved by currently available vaccines in the United States and other Western countries, per research.

“This announcement is an important first step in vaccinating the world and halting the pandemic,” said Hotez in a statement. “Our vaccine technology offers a path to address an unfolding humanitarian crisis, namely the vulnerability the low- and middle-income countries face against the delta variant. Widespread and global vaccination with our Texas Children’s-Baylor-BE vaccine would also forestall the emergence of new variants. We have previously missed that opportunity for the alpha and delta variant. Now is our chance to prevent a new global wave from what might follow.”

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

7+ can't-miss Houston business and innovation events for November

where to be

Editor's note: From life sciences to space and energy, Houston's most notable sectors will host signature conferences and opportunities to connect this month. Here’s what not to miss in November and how to register. Please note: this article may be updated to add more events.

Nov. 4 — Startup Heat Simulation

Build a team and simulate fundraising, team building, resource allocation and go-to-market decisions that real founders face in their startup journey. This in-person simulation event helps prepare participants for when the stakes are real.

This event is Wednesday, Nov. 4, from 9 a.m.-noon at the Ion. Register here.

Nov. 9 — HAN Life Science Kick-off

Houston Angel Network will host this engaging event focused on AI in the clinical space. Expect panel discussions, networking and pitches from HAN portfolio companies. Dr. Peter Pisters, former president of M.D. Anderson, will deliver a keynote address.

This event is Monday, Nov. 9, from 4-8 p.m. at the Texas A&M School of Engineering and Medicine. Register here.

Nov. 10 — Texas Life Science Forum

Rice Alliance and BioHouston will host the 15th annual Texas Life Science Forum this month, bringing together industry, emerging life science companies, academics and investors. Nearly 50 companies will present their novel concepts during the event. Michael Tores, founder and former CEO of CrossBridge Bio, will be featured in a fireside chat. Dr. Arthur Sands, president and CEO of Nurix, will present the keynote address.

This event is Tuesday, Nov. 10, from 4-5:15 p.m. at Rice University's McNair Hall. Register here.

Nov. 11 — Envision 2026: Clinical Research, Reimagined

TMCi's annual Envision conference returns this month. This year, the event will take a look at what sets Houston apart as a hub for clinical research and how TMC is exploring strategies to address the roadblocks Houston and Texas face in clinical trial efficiency.

This event is Wednesday, Nov. 11, from 3:30-6 p.m. at TMC Innovation Factory. Register here.

Nov. 11 — First Principles: Inside the Texas A&M Space Institute

Dr. Rob Ambrose, associate director of the Texas A&M Space Institute, will present on the Texas A&M Space Institute's planned 400,000-square-foot facility at NASA’s Exploration Park at the latest installment of this series. A moderated Q&A will follow.

This event is Wednesday, Nov. 11, from 3:30-6 p.m. at TMC Innovation Factory. Register here.

Nov. 12 — Technology Transfer Thursdays

Join for the third installment of Tech Transfer Thursdays, hosted by Rice University's Office of Technology Transfer. The event series focuses on how emerging university research can become commercial ventures. This month's event will focus on artificial intelligence and quantum computing. Stick around after for a community happy hour.

This event is Thursday, Nov. 12, from 5:30-7 p.m. at the Ion. Register here.

Nov. 12 — Transition on Tap

Greentown Labs’ signature networking event returns in November to foster conversations and connections within Houston's climate and energy transition ecosystem. Entrepreneurs, investors, students, philanthropists and more are invited to attend, meet colleagues, discuss solutions and engage with the growing community.

This event is Thursday, Nov. 12, from 5:30-7 p.m. at Greentown Labs. Register here.

Nov. 18-19 — American Data Centers & AI Conference and Exhibition 2026

Set to redefine the intersection of energy and digital infrastructure, the American Data Centers & AI Conference and Exhibition convenes in Houston for its second annual event. The event will address the increasing demand for high-performance computing and the sustainable development of AI infrastructure, which requires significant power. Participants can expect to learn about practical solutions in energy integration, modern data center design, and scalable approaches. The agenda includes presentations from leading experts, demonstrations of new technologies for thermal management and grid optimization, and detailed discussions on AI's environmental impact and how to reuse generated heat.

This event begins Nov. 18 at the DoubleTree Hotel at Greenway Plaza. Register here.

7 finalists compete to be crowned Houston's 2026 Startup of the Year

Cast Your Vote

Each year, the Houston Innovation Awards program recognizes the best and brightest in the local innovation community. And while most of the award winners are selected by our esteemed panel of judges, one winner is determined by you.

Voting is now open for our people's choice award: 2026 Startup of the Year. Seven exceptional finalists are in the running for the title, and your votes will determine who wins.

From innovative platforms benefiting the education, commerce, health, investment and IT sectors to next-gen memory technology and improvements for robotic supply chains, these startups are making an impact in Houston and beyond.

Read about our Startup of the Year finalists and their missions and achievements below, then cast your vote. You can vote once per day through Nov. 13, so make your voice heard.

The winner, along with the winners in all other categories, will be revealed in mid-November right here on InnovationMap.com. Stay tuned.

FluxWorks

FluxWorks

Fluxworks is aiming to shape the future of the robotic supply chain with its flagship Celestial Gear. The magnetic gearbox offers a contactless design that leads to less wear, debris and maintenance. In 2026, Fluxworks closed a $5 million seed round to scale the product.

IronLattice

IronLattice

IronLattice is developing next-generation, ferroelectric memory technology for AI and high-performance computing workloads. In June 2026, the company closed a $3 million angel round. It began wafer production this fall, with its first working device targeted for completion in spring 2027.

Lumino

Lumino

Lumino is a unified commerce ecosystem and payments platform designed to provide businesses with the technology, payments infrastructure, intelligence and tools they need to grow while creating impact in their communities. Lumino publicly launched its platform in 2026 in Houston and is rolling out its next stage of global expansion.

Progress Report

Progress Report is a K-12 learning-intelligence platform designed to go beyond identifying that a student is struggling. It traces performance to learning gaps and prerequisite skills, helping educators understand where a student is struggling and what may be causing it. Progress Report recently released a fully built production platform and launched pilots with 35 educators and 200 students across Texas and Arizona.

Rosarium Health

Rosarium Health is a platform that coordinates the full process for home accessibility upgrades and modifications for seniors and people living with disabilities. In 2026, the startup announced $6 million in seed funding and scaled to a national network of 800-plus clinicians and 3,000-plus contractors.

Thread

Thread

Thread is building an AI-powered service desk platform for Managed Service Providers (MSPs). Its technology combines agentic AI, assistive AI, automation, and real-time communication to help MSPs resolve IT support requests faster and with less manual work.

TokenRoster

TokenRoster is an AI-powered assessment platform for early-stage startups, providing founders with an investor-grade evaluation of their company before the pitch and giving investors a curated roster of vetted companies. Since launch, TokenRoster has grown to 65 companies and 43 founder accounts, with 10 assessment frameworks available.